Core Insights - Polaryx Therapeutics is advancing its investigational therapy PLX-200 for Krabbe disease, presenting new data at the 22nd Annual WORLDSymposium™ [1][2] - The SOTERIA trial, a Phase 2 study, aims to assess the safety and efficacy of PLX-200 across multiple lysosomal storage disorders (LSDs) [2][5] Company Overview - Polaryx Therapeutics is a clinical-stage biotechnology company focused on developing therapies for rare orphan lysosomal storage disorders, founded in 2014 [7] - The company aims to deliver patient-friendly treatments that address the underlying pathophysiology of these diseases [7] Product Information - PLX-200 is an orally available compound based on gemfibrozil, which has been used in adults but never approved for pediatric indications [4] - The drug's ability to cross the blood-brain barrier positions it as a potential treatment for multiple rare LSDs [4] Clinical Trial Details - The SOTERIA trial will include patients with CLN2, CLN3, Krabbe disease, and Sandhoff disease, representing about 25% of the LSD population [5] - The trial is designed to be flexible and resource-efficient, with plans to initiate in the first half of 2026 [5][6] Presentation Information - Shrijay Vijayan, Chief Scientific and Business Development Officer, will present preclinical findings on PLX-200 in a mouse model of Krabbe disease on February 6, 2026 [3]

Core Insights - Polaryx Therapeutics has announced the commencement of trading of its common stock on the Nasdaq Capital Market under the ticker symbol "PLYX" [1][2] - The listing is viewed as a significant milestone for the company, marking a new phase in its development and potential opportunities in the rare lysosomal storage disorders (LSDs) market [2] - The company is set to launch the SOTERIA trial in the first half of 2026, which will evaluate the safety and efficacy of its lead drug candidate, PLX-200, across multiple LSD indications [2][3] Company Overview - Polaryx Therapeutics is a clinical-stage biotechnology company focused on developing therapies for rare orphan lysosomal storage disorders [4] - Founded in 2014, the company aims to provide safe and effective treatments that address the underlying pathophysiology of these diseases [4] - The lead product candidate, PLX-200, targets several LSDs and is part of a broader strategy that includes small molecule therapies and gene therapy [4] SOTERIA Trial Details - The SOTERIA trial is a Phase 2, open-label, single-arm study designed to assess the safety, tolerability, and clinical activity of PLX-200 in patients with CLN2, CLN3, Krabbe disease, and Sandhoff disease [3] - The trial is expected to include sites in the United States, Europe, and Asia, and aims to validate PLX-200's preclinical science while gathering critical data for future development [3] - A natural history study will serve as a control arm for the CLN2 and CLN3 cohorts, providing comparative data against PLX-200's treated arm [3]

Core Insights - Polaryx Therapeutics has received approval for a direct listing on the Nasdaq Capital Market under the ticker symbol "PLYX," with trading expected to commence on or about February 2, 2026 [1][2] - The company is focused on developing disease-modifying therapies for rare pediatric lysosomal storage disorders (LSDs) and plans to launch a Phase 2 trial named SOTERIA to assess the safety and efficacy of its lead drug candidate, PLX-200 [2][4] Company Overview - Polaryx Therapeutics is a clinical-stage biotechnology company founded in 2014, dedicated to developing small molecule and gene therapy treatments for rare orphan LSDs [4] - The company aims to deliver safe and effective treatments that address the underlying pathophysiology of LSDs, utilizing a combination of small molecule therapies and gene therapy [4] - PLX-200 is the most advanced product candidate targeting multiple LSDs, with the upcoming SOTERIA trial designed to validate its safety and efficacy [4] Investor Relations - Polaryx plans to launch a new Investor Relations section on its website, which will serve as a central resource for stockholders, providing information such as stock details, press releases, and FAQs [3]

AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 ___________________________ Polaryx Therapeutics, Inc. (Exact name of registrant as specified in its charter) ___________________________ (State or other jurisdiction of incorporation or organization) As filed with the Securities and Exchange Commission on January 27, 2026 Registration No. 333-291681 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Primary Standard Industrial Classification Code Numbe ...

As filed with the Securities and Exchange Commission on January 13, 2026 Registration No. 333-291681 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 ___________________________ Polaryx Therapeutics, Inc. (Exact name of registrant as specified in its charter) ___________________________ (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Numbe ...

Core Insights - Donovan Jones is an IPO research specialist with 15 years of experience in identifying high-quality IPO opportunities [1] - He leads the investing group IPO Edge, which provides actionable information on growth stocks through various resources including IPO filings, previews, calendars, and a comprehensive guide to IPO investing [1] Group 1 - IPO Edge offers a database of U.S. IPOs and tracks upcoming IPOs, facilitating investors in navigating the IPO lifecycle from filing to listing [1] - The group emphasizes the importance of understanding the quiet period and lockup expiration dates in the IPO process [1]

As filed with the Securities and Exchange Commission on November 20, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 ___________________________ Polaryx Therapeutics, Inc. (Exact name of registrant as specified in its charter) ___________________________ (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 2834 47-339365 ...